Maze Therapeutics (MAZE) said Wednesday its experimental oral medication demonstrated a 35.6% average reduction in a key marker of kidney damage during a Phase 2 clinical trial.

The stock fell 32% as intraday volume topped 6.26 million shares, compared with the daily average of 488,452.

Anavex Life Sciences (AVXL) withdrew its application for marketing authorization of its experimental drug blarcamesine in the EU as an add-on treatment for early Alzheimer's disease in adults.

The company said the decision follows feedback from the European Medicines Agency's Committee for Medicinal Products for Human Use, indicating it would not be in a position to issue a positive opinion.

The stock fell 31% as volume topped 9.92 million shares, versus the daily average of 1.38 million.

Micron Technology (MU) commenced offers to purchase six series of outstanding senior notes, with maturities ranging from 2031 to 2035.

The stock fell 3.9% as volume topped 41.3 million shares, versus the daily average of almost 36.4 million.

Price: 33.26, Change: -15.74, Percent Change: -32.12